At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Sia Daneshmand, MD, of University of Southern California, provides overviews and updates from three clinical trials involving cretostimogene for High-Risk NMIBC: CORE-008, BOND-003, and PIVOT-006.
Cretostimogene for High-Risk NMIBC: CORE-008, BOND-003, and PIVOT-006
By Sia Daneshmand, MD - Last Updated: February 20, 2025Related Posts
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.